InMed Pharmaceuticals and the Almac Group have partnered on a proprietary approach to augment current biosynthesis-based methods for cannabinoid production.   Over the last several months, InMed and Almac have been engaged in developing a streamlined cannabinoid manufacturing process, specifically optimizing the upstream cannabinoid assembly processes as well as downstream purification, to achieve cost efficient, GMP-grade active pharmaceutical ingredients for prescription-based medications.   &...